GSEP
SMMT icon

Golden State Equity Partners’s Summit Therapeutics SMMT Stock Holding History

Golden State Equity Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40
Closed -$758 – 1535
2026
Q1 		$758 Buy
+40
New +$647 ﹤0.01% 1819

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Golden State Equity Partners's SMMT Position: Q2 2026 in Review

Golden State Equity Partners sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 40 shares — an estimated $758 sold.

Golden State Equity Partners first reported a position in SMMT in Q1 2026 and held it in 1 quarter. The position peaked at $758 in Q1 2026. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Golden State Equity Partners reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 40 Summit Therapeutics shares in Q2 2026, an estimated $758.
  • Golden State Equity Partners first reported a position in Summit Therapeutics in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Summit Therapeutics position peaked at $758 in Q1 2026.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.